Facebook link Linked In link You Tube link
  • Education2015

    Share Your Science

    Attendees from around the globe share their research and advance their careers. See their work

  • FOCIS 2017 slider

    FOCIS 2017

    Registration and abstract submission will open soon for THE meeting in translational immunology.

  • Science Immunology Homepage Slider

    New Journal Showcasing Innovative Advances


    FOCIS members receive complimentary access to the journal. Read the current issue.
  • Industry2015

    Industry Partnership

    FOCIS provides a plethora of opportunities for industry to interact with immunology experts from around the world. Learn more.

The Federation of Clinical Immunology Societies (FOCIS) exists to improve human health through immunology by fostering interdisciplinary approaches to both understand and treat immune-based diseases. Initially established as a cross-disciplinary meeting, FOCIS held its first Annual Meeting in 2011 and we look forward to seeing you at our 17th Annual Meeting in Chicago, Illinois!  

News & Information

Visit www.IBECollaborative.com and earn CME/CNE today!

FOCIS 2016 Highlights

Thank you to everyone who participated in FOCIS 2016! 

Over 800 attendees, 365 abstracts, 53 speakers, from 27 countries created an exceptional atmosphere for THE meeting for translational immunology.

Special thanks goes out to the FOCIS 2016 Scientific Program Committee for their time and talent in putting together a stellar lineup of topics and speakers.

View the FOCIS 2016 Facebook Photo Album

FOCIS Executive Office Staff Announcement

On June 1, Mike Mathy began as Interim Executive Director. Mike is an award-winning and experienced association management professional who is steeped in the FOCIS culture, as he previously served as Associate Executive Director. He has a thorough understanding of revenue generation, strategic communications and collaborative project management and has served at the helm of several educational-based non-profit organizations.

Read more...

All Articles...

 

 FOCIS 2016 Sponsors

use

 

ePub header 2016

September 9, 2016
 
EDITOR: Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital  EDITORIAL BOARD: Abul K. Abbas, MD, University of California, San Francisco | Carla J. Greenbaum, MD, Benaroya Research Institute | Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital

Highlights from Recent Literature

circlearrow2 Inflammatory Serum Proteins Augment Prognostic Potential of ANAs for SLE
 

Review of:
Rufei Lu, et al. Dysregulation of Innate and Adaptive Serum Mediators Precedes Systemic Lupus Erythematosus Classification and Improves Prognostic Accuracy of Autoantibodies. J Autoimmun. 2016 Jun 20. pii: S0896-8411(16)30079-8. doi: 10.1016/j.jaut.2016.06.001. PMID: 27338520.

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by chronic inflammation and often the presence of antinuclear antibodies (ANA) to double-stranded DNA (dsDNA), anti-Ro/SSA and other nuclear antigens. The heterogeneous nature of the disease contributes to delays in diagnosis and early intervention. A variety of markers have been associated with preclinical or clinical disease, such as the presence of specific serum ANAs, elevated serum cytokine levels or increased expression of interferon (IFN) inducible genes (or IFN signature) found in peripheral blood cells or target tissues. While these indicators have been associated with disease pathogenesis, no single marker examined can be used as a prognostic indicator of preclinical disease or disease progression.

readmore

 
  Reviewed by Laurie Davis, PhD, and Anne B. Satterthwaite, PhD, UT Southwestern Medical Center

 

Developments in Basic Immunology and Novel Therapies

circlearrow2 Natural Killer Cells and Myeloid Malignancies: Hide and Seek
 

Myeloid malignancies: a heterogeneous group of diseases which incidence is increasing with age

Myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML) are clonal myeloid disorders arising in the bone marrow (BM) where blasts are blocked in their differenciation. MDS evolution is dominated by the risk of progression into AML, occurring in about 30% of the cases. The annual overall incidence of AML is 3.8 cases per 100,000 adults in western countries, increasing to 15 cases per 100,000 for elderly over 60 years old. Many advances have been made in the molecular characterization of the disease and the evaluation of molecular markers in specific cytogenetic AML subsets is now a standard procedure for patient’s diagnosis and risk stratification (1). Current views of leukemogenesis assume that hematopoietic stem cells (HSC) accumulate somatic mutations and give rise to AML initiating cells following a clonal selection process, at diagnosis but also after relapse. This long-duration of the malignant development process, in parallel with patient’s aging, questions the nature of the stimuli leading to this evolution, why particular successive mutations are required to ensure AML survival and proliferation, and how the organism’s environment, including the immune system, can deal with the emerging preleukemic and leukemic cells (2).

readmore

 
  Submitted by Antoine Toubert and Nicolas Dulphy, Université Paris Diderot, Sorbonne Paris Cité, INSERM U.1160 and AP-HP Hôpital Saint-Louis

 

Selected Recent Clinical Trial Results

circlearrow2 Safety and Efficacy of Subcutaneous Toclizumab in Adults with Systemic Sclerosis (faSScinate): A Phase 2, Randomised, Controlled Trial 
 

Clinical Trial: Khanna D, Denton C, Jahreis A, et al. Lancet 2016; 387: 2630-40

Disease: Systemic sclerosis 

Intervention: Subcutaneous tocilizumab or placebo. Tocilizumab is an interleukin 6 (IL-6) receptor-α inhibitor

readmore

 
  Submitted by Sandra Lord, MD, Benaroya Research Institute. Edited by Carla J. Greenbaum, MD, Benaroya Research Institute  

Thank you to the 2013 FOCIS Corporate Council:

Amgen 4 Blue      Beckman      CelgeneLogo      genentech color

   

Share